Nitrous Acid

Nitrous Acid

SCHEMBL15399059

CCC(CCSC)n1cc(-c2ncnc3[nH]ccc23)cn1.O=NO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 19/20 0.58
JAK1 P23458 12/20 0.58
HDAC6 Q9UBN7 8/20 0.53
JAK3 P52333 7/20 0.53
TYK2 P29597 6/20 0.53
HDAC1 Q13547 6/20 0.53
HDAC3 O15379 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53
NCOR2 Q9Y618 2/20 0.53
HDAC9 Q9UKV0 1/20 0.53
RET P07949 3/20 0.49
ROCK1 Q13464 3/20 0.49
DAPK3 O43293 2/20 0.49
PAK4 O96013 2/20 0.49
ABL1 P00519 2/20 0.49
LTK P29376 2/20 0.49
CSNK1A1 P48729 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29540937 0.94 JAK2 (0.63) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL28107513 0.94 JAK2 (0.63) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL29540692 0.85 JAK2 (0.64) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL98856 0.85 JAK2 (0.64) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL4115196 0.85 JAK2 (0.70) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL13695658 0.85 JAK2 (0.69) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL13695710 0.83 JAK2 (0.80) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL100270 0.83 JAK2 (0.79) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL19062242 0.83 JAK2 (0.79) JAK2JAK1HDAC6JAK3TYK2
SCHEMBL20873092 0.82 JAK2 (0.54) JAK2JAK1HDAC6JAK3TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11331320-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-05-17 US disclosed
US-20200338077-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2020-10-29 US disclosed
US-20180338978-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE HOLDINGS CORPORATION 2018-11-29 US disclosed
US-9662335-B2 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-05-30 US disclosed
US-20160272648-A1 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors INCYTE CORPORATION 2016-09-22 US disclosed
US-9206187-B2 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase INCYTE HOLDINGS CORPORATION (US) 2015-12-08 US disclosed
US-20140243360-A1 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-20140005210-A1 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors INCYTE CORPORATION (US) 2014-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243360-A1 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885HDAC6 2492/4885
US-20200338077-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885HDAC6 2492/4885
US-20180338978-A1 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885HDAC6 2492/4885
US-20140005210-A1 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885HDAC6 2492/4885
US-11331320-B2 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885HDAC6 2492/4885
US-20160272648-A1 Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors JAK3, JAK1, JAK2 JAK2 3/4885JAK1 2/4885HDAC6 2492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.